Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Income from Continuing Operations (2016 - 2025)

vTv Therapeutics' Income from Continuing Operations history spans 12 years, with the latest figure at 7138000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 60.87% year-over-year to 7138000.0; the TTM value through Dec 2025 reached 31080000.0, down 36.89%, while the annual FY2025 figure was 31080000.0, 36.89% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 7138000.0 at vTv Therapeutics, up from 10345000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 841000.0 in Q2 2021 and bottomed at 10345000.0 in Q3 2025.
  • The 5-year median for Income from Continuing Operations is 6054500.0 (2022), against an average of 6127000.0.
  • The largest YoY upside for Income from Continuing Operations was 83.15% in 2021 against a maximum downside of 689.17% in 2021.
  • A 5-year view of Income from Continuing Operations shows it stood at 9468000.0 in 2021, then surged by 35.68% to 6090000.0 in 2022, then rose by 27.08% to 4441000.0 in 2023, then grew by 0.09% to 4437000.0 in 2024, then tumbled by 60.87% to 7138000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Income from Continuing Operations are 7138000.0 (Q4 2025), 10345000.0 (Q3 2025), and 7380000.0 (Q2 2025).